Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats

被引:47
作者
Kageyama, M [1 ]
Namiki, H [1 ]
Fukushima, H [1 ]
Terasaka, S [1 ]
Togawa, T [1 ]
Tanaka, A [1 ]
Ito, Y [1 ]
Shibata, N [1 ]
Takada, K [1 ]
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078414, Japan
关键词
ritonavir; induction; cytochrome P450 3A; chronic administration; P-glycoprotein; pharmacokinetic;
D O I
10.1248/bpb.28.130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ritonavir (RTV) is well known as an inhibitor of many drugs that are metabolized by cytochrome P450 (CYP) 3A or fluxed via P-glycoprotein (Pgp), although it is also reported that RTV is a potent inducer for them. In this study, to elucidate these contradictory phenomena, functional changes of CYP3A or Pgp during chronic administration of RTV were examined in rats. After pretreatment with RTV for indicated days (day 3-day 14), rats were used in the experiments. The area under the plasma drug concentration vs. time curve (AUC(0-infinity)) after oral administration of RTV (20 mg/kg) to these rats showed an RTV-treatment period-dependent decrease, and the mean AUC(0-infinity) of RTV in Day 14 rats decreased significantly by 57% as compared to the control. The AUC(0-infinity) after intravenous (i.v.) administration of RTV to Day 3 and Day 5 rats increased significantly by 28% and 22%, respectively, while there were no significant changes in the AUC(0-infinity) in Day 7 and Day 14 rats as compared to the control. As for i.v. administration of erythromycin (EM) or midazolam (MDZ) to RTV-treated rats, the AUC(0-infinity) in Day 3 and Day 5 rats increased significantly as compared to the control, while in Day 7 rats and rifampicin-treated rats, the AUC(0-infinity) of EM decreased significantly by 82% and 42%, respectively, as compared to the control. For MDZ, there were no significant changes in the AUC(0-infinity) in Day 7 or Day 14 rats. After i.v. administration of rhodamine123 (Rho123), the excretion clearances from blood circulation to the intestinal lumen and the biliary excretion clearances in Day 14 rats increased markedly by 2.2-fold and 2.6-fold as compared to the control. It has been confirmed that RTV is not only a potent inhibitor but also a potent inducer of CYP3A, and that RTV is a potent inducer of intestinal Pgp. This property of RTV is responsible for regulating the oral bioavailability of drugs that are mediated by CYP3A and Pgp.
引用
收藏
页码:130 / 137
页数:8
相关论文
共 37 条
[1]   Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations [J].
Barry, M ;
Gibbons, S ;
Back, D ;
Mulcahy, F .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :194-209
[2]  
Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009
[3]   BILIARY-EXCRETION OF ERYTHROMYCIN AFTER PARENTERAL ADMINISTRATION [J].
CHELVAN, P ;
HAMILTONMILLER, JMT ;
BRUMFITT, W .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 8 (03) :233-235
[4]  
Choo EF, 2000, DRUG METAB DISPOS, V28, P655
[5]   Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers [J].
Ding, R ;
Tayrouz, Y ;
Riedel, KD ;
Burhenne, J ;
Weiss, J ;
Mikus, G ;
Haefeli, WE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (01) :73-84
[6]   L-735,524 - THE DESIGN OF A POTENT AND ORALLY BIOAVAILABLE HIV PROTEASE INHIBITOR [J].
DORSEY, BD ;
LEVIN, RB ;
MCDANIEL, SL ;
VACCA, JP ;
GUARE, JP ;
DARKE, PL ;
ZUGAY, JA ;
EMINI, EA ;
SCHLEIF, WA ;
QUINTERO, JC ;
LIN, JH ;
CHEN, IW ;
HOLLOWAY, MK ;
FITZGERALD, PMD ;
AXEL, MG ;
OSTOVIC, D ;
ANDERSON, PS ;
HUFF, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (21) :3443-3451
[7]   P-glycoprotein-mediated intestinal and biliary digoxin transport in humans [J].
Drescher, S ;
Glaeser, H ;
Mürdter, T ;
Hitzl, M ;
Eichelbaum, M ;
Fromm, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (03) :223-231
[8]   HIV protease inhibitor ritonavir:: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833 [J].
Drewe, J ;
Gutmann, H ;
Fricker, G ;
Török, M ;
Beglinger, C ;
Huwyler, J .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (10) :1147-1152
[9]  
Gao Weihua, 2002, Antiviral Chemistry & Chemotherapy, V13, P17
[10]   Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir [J].
Gisolf, EH ;
van Heeswijk, RPG ;
Hoetelmans, RWM ;
Danner, SA .
AIDS, 2000, 14 (07) :801-805